Cleave Therapeutics
Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
Launch date
Employees
Market cap
-
Enterprise valuation
€44—65m (Dealroom.co estimates Aug 2019.)
San Francisco California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$44.0m | Series A | ||
$10.0m | Series A | ||
$10.0m | Series A | ||
N/A | - | ||
$26.0m | Series B | ||
$26.0m | Series B | ||
$12.0m | Series C | ||
Total Funding | €116m |
Recent News about Cleave Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.